IDO1 and cancer: IDO1 has been demonstrated as expressing in 58% of human cancers [18], and its expression levels are correlated with the poor clinical outcome in several cancer types, such as melanoma, gynaecological cancers like endometrial carcinoma, liver and ovarian cancers [19,20,21,22,23,24,25].